New York State Common Retirement Fund Cuts Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

New York State Common Retirement Fund lowered its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 72.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 256,484 shares of the biopharmaceutical company's stock after selling 686,630 shares during the quarter. New York State Common Retirement Fund owned 0.08% of Amicus Therapeutics worth $2,093,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Virtus Fund Advisers LLC purchased a new position in Amicus Therapeutics during the fourth quarter valued at $29,000. Covestor Ltd increased its position in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 2,312 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Amicus Therapeutics in the fourth quarter valued at approximately $59,000. GAMMA Investing LLC grew its holdings in shares of Amicus Therapeutics by 1,610.8% in the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 7,007 shares in the last quarter. Finally, Thrivent Financial for Lutherans acquired a new position in Amicus Therapeutics during the 4th quarter worth approximately $104,000.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock traded down $0.22 during trading hours on Friday, reaching $6.06. 3,505,161 shares of the stock were exchanged, compared to its average volume of 4,104,743. The stock has a market cap of $1.87 billion, a P/E ratio of -67.33 and a beta of 0.51. The company has a debt-to-equity ratio of 2.02, a quick ratio of 2.47 and a current ratio of 3.34. Amicus Therapeutics, Inc. has a 52-week low of $5.51 and a 52-week high of $12.65. The firm's 50 day moving average is $6.08 and its 200 day moving average is $7.56.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. UBS Group boosted their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group reduced their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.